Seth T Lirette (Seth Lirette)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Pregnancy Outcomes

Magnetic Resonance

Cardiovascular Disease

Polycystic Ovary Syndrome

Top Venues

Journal of the Endocrine Society

Annals of internal medicine

Neuro-oncology advances

This page only lists publications with an associated author ORCID identifier.

Publications

Tulika Ranjan, Alexander K Yu, Shaed Elhamdani, Candace M Howard, Seth T Lirette, Krista L Denning, Jagan Valluri, Pier Paolo Claudio
Treatment of unmethylated MGMT-promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients' healthcare costs. Neuro-oncology advances 5 (1) (2023)
Maria Clarissa Tio, Xiaoqian Zhu, Seth T Lirette, Andrew D Rule, Kenneth R Butler, Michael E Hall, Neville R Dossabhoy, Thomas Mosley, Tariq Shafi
External Validation of a Novel Multi-Marker Glomerular Filtration Rate Estimating Equation. Kidney360 (2023)
Tariq Shafi, Xiaoqian Zhu, Seth T Lirette, Andrew D Rule, Thomas Mosley, Kenneth R Butler, Michael E Hall, Pradeep K Vaitla, James J Wynn, Maria Clarissa Tio, Neville R Dossabhoy, Eliseo Guallar, Javed Butler
Quantifying Individual-Level Inaccuracy in Glomerular Filtration Rate Estimation : A Cross-Sectional Study. Annals of internal medicine 175 (8) (2022)
Jacob E Pruett, Seth T Lirette, Damian G Romero, Licy L Yanes Cardozo
Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women. Journal of the Endocrine Society 7 (2) (2022)
Jacob E Pruett, Seth T Lirette, Damian G Romero, Licy L Yanes Cardozo
Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women. Journal of the Endocrine Society 7 (2) (2022)
Jacob E Pruett, Seth T Lirette, Damian G Romero, Licy L Yanes Cardozo
Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women. Journal of the Endocrine Society 7 (2) (2022)